[{"from": "human", "value": "Create a molecule that satisfies the conditions outlined in the description. The molecule is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Mavelertinib specifically binds to and inhibits EGFR T790M, a secondary acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR/T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which can inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization."}, {"from": "gpt", "value": "[C][N][C][=C][Branch1][=Branch2][C][=Branch1][Ring2][=N][Ring1][Branch1][O][C][N][C][=C][C][=Branch2][Ring1][O][=N][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][C][C@H1][Branch1][Branch2][C@@H1][Branch1][Ring2][C][Ring1][Branch1][F][N][C][=Branch1][C][=O][C][=C][N][Branch1][=Branch1][C][=N][Ring2][Ring1][Ring1][C]"}]